About the Company
We do not have any company description for Elevation Oncology, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Elevation Oncology, Inc.
What's Going On With Elevation Oncology Stock? - Benzinga
Elevation Oncology, Inc. (NASDAQ: ELEV) shares raced higher Monday. The company announced program updates and upcoming 2024 milestones on Friday.
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Recommendation ...
Elevation Oncology has a 1-year low of $0.22 and a 1-year high of $4.33. The firm has a market cap of $19.69 million, a price-to-earnings ratio of -0.41 and a beta of 1.59.
Elevation Oncology’s Q3 2024 Highlights and Financial Report
Elevation Oncology, Inc. is an innovative biotechnology company dedicated to developing selective cancer therapies targeting solid tumors with significant unmet medical needs. Their lead product ...
Elevation Oncology Enters into Agreement to Be Acquired by Concentra ...
BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat ...
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...
Elevation Oncology to Present at the Piper Sandler 36th Annual ...
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...
Elevation Oncology Announces First Patient Dosed in the Phase 1 ...
NEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Investors might want to bet on Elevation Oncology, Inc. (ELEV), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...
Elevation Oncology Appoints Experienced Clinical Development Leaders ...
BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat ...
Elevation Oncology Reports Third Quarter 2023 Financial Results and ...
BOSTON, Nov. 2, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across ...
Elevation Oncology to Participate in Upcoming Investor Conferences
BOSTON, Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat ...
Similar Companies
Loading the latest forecasts...